TransMedics Group, Inc. Aktie News

TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lung, and liver transport. Profitability and margins are improving, though free cash flow, dilution, and a limited TAM remain concerns.

Shares in TransMedics soared tenfold in the last three years, plunged in January, and have recovered of late.

ANDOVER, Mass. , July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025.

TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics ...

Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Positive, company-specific developments have led to shares of TransMedics Group (TMDX 1.08%) and FuboTV (FUBO 2.32%) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks.

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beat...